NOPAIN for Veterans Act
- Sponsor
- Sen. Capito, Shelley Moore [R-WV]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Nov 19, 2025
Bottom line
The NOPAIN for Veterans Act aims to expand access to non-opioid pain management options for veterans by requiring their timely inclusion in the VA's national formulary.
What it actually does
This bill mandates that the Department of Veterans Affairs (VA) include certain non-opioid pain management drugs and biological products in its national formulary. It defines these products as those approved by the Food and Drug Administration (FDA) to reduce postoperative pain, produce postsurgical or regional analgesia, or treat acute pain without acting on opioid receptors. The bill sets specific timelines for their inclusion and prohibits the use of funds from the Cost of War Toxic Exposures Fund for this purpose.
Proponents argue
Supporters argue that this bill is a crucial step in combating the opioid crisis among veterans by ensuring they have access to the latest non-addictive pain management alternatives. They contend that mandating inclusion in the VA formulary will standardize care, reduce reliance on opioids, and improve the quality of life for veterans suffering from acute and postoperative pain, aligning VA practices with modern pain management protocols.
Opponents contend
Critics might argue that mandating specific drug inclusions could limit the VA's clinical autonomy and formulary management flexibility, potentially leading to increased costs or the inclusion of less cost-effective options. They may also raise concerns about the financial implications of such mandates without dedicated funding, potentially diverting resources from other critical veteran services.
The bill is very short and clear, making it highly accessible for a reader to understand its core provisions and implications within a short timeframe.
Section 2(a)(1) and (3)
Mandatory Inclusion of Non-Opioid Pain Medications in VA Formulary
This provision requires the Secretary of Veterans Affairs to add specific non-opioid pain management drugs and biological products to the VA's national formulary. These products must be FDA-approved for reducing postoperative pain, providing postsurgical or regional analgesia, or treating acute pain without engaging opioid receptors. The inclusion must occur within one year of the product becoming eligible for certain temporary additional payments under the Social Security Act, or 18 months after FDA approval, whichever comes first.
Supporters argue
Proponents argue that this mandate ensures veterans receive timely access to the most advanced non-addictive pain treatments, directly addressing the opioid epidemic and improving patient outcomes. They believe it removes potential bureaucratic hurdles that might delay access to these critical medications.
Critics contend
Opponents might contend that such mandates can restrict the VA's ability to make cost-effective purchasing decisions or prioritize drugs based on its own clinical assessments and budget constraints. They may argue that the VA should retain flexibility to manage its formulary based on a comprehensive review of efficacy, safety, and cost.
Tradeoffs
This provision balances the goal of rapidly expanding non-opioid access for veterans against the VA's traditional autonomy in managing its drug formulary and procurement, potentially impacting budget flexibility and internal clinical review processes.
Section 2(b)
Funding Limitation for Non-Opioid Mandate
This section explicitly states that none of the funds from the Cost of War Toxic Exposures Fund, established under section 324 of title 38, United States Code, may be used to implement the amendments made by this Act. This means that the costs associated with including new non-opioid pain medications in the VA formulary must be covered by other VA appropriations.
The bill establishes specific, relatively aggressive timelines for the VA to include non-opioid pain management drugs in its national formulary: either one year after eligibility for temporary additional payment under the Social Security Act or 18 months after FDA approval, whichever is earlier.
Section 2(a)(3), new subsection (d)(1) and (2)
Why it matters:This is standard legislative practice for specifying implementation details and ensuring legal precision, rather than an attempt to obscure the information.
Case for: Supporters argue that these explicit and relatively short timelines are crucial for ensuring veterans gain rapid access to new, effective non-opioid treatments, preventing delays that could prolong opioid dependence or untreated pain.
Case against: Some might argue that such rigid timelines could pressure the VA to incorporate drugs without sufficient time for comprehensive internal review, cost-benefit analysis, or negotiation for favorable pricing, potentially leading to less efficient use of resources.
Estimated impact: Ensures a faster adoption rate for new non-opioid pain medications within the VA system.